| #1 | Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI | PVALB | 1.000 | $0.96 | SDA-2026-04-03-26abc |
| #2 | Metabolic Reprogramming to Reverse Senescence | SIRT1,PGC1A,NAMPT | 1.000 | $0.98 | SDA-2026-04-04-gap-s |
| #3 | TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration | TREM2 | 0.990 | $0.87 | SDA-2026-04-03-gap-a |
| #4 | SASP Modulation Rather Than Cell Elimination | NFKB1,IL1B,BDNF | 0.981 | $0.97 | SDA-2026-04-04-gap-s |
| #5 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal gamma oscillations via upstream perforant path gating in Alzheimer's disease | SST | 0.948 | $0.96 | SDA-2026-04-03-26abc |
| #6 | PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction | PLCG2 | 0.941 | $0.82 | SDA-2026-04-01-gap-0 |
| #7 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to prevent tau propagation and restore entorhinal-hippocampal gamma synchrony in early Alzheimer's disease | SST | 0.922 | $0.85 | SDA-2026-04-03-26abc |
| #8 | CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal | CYP46A1 | 0.921 | $0.80 | SDA-2026-04-01-gap-l |
| #9 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.921 | $0.93 | SDA-2026-04-04-gap-s |
| #10 | HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM Transition | HK2 | 0.919 | $0.91 | SDA-2026-04-16-gap-d |
| #11 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.919 | $0.80 | SDA-2026-04-16-gap-b |
| #12 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | SMPD1 | 0.910 | $0.79 | SDA-2026-04-03-gap-a |
| #13 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.907 | $0.81 | SDA-2026-04-03-gap-a |
| #14 | Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma gating and block tau propagation in AD | SST | 0.900 | $0.95 | SDA-2026-04-03-26abc |
| #15 | CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset | CSF1R | 0.898 | $0.85 | SDA-2026-04-16-gap-d |
| #16 | Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant-path gamma gating in AD | SST | 0.896 | $0.78 | SDA-2026-04-03-26abc |
| #17 | SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence | SIRT1 | 0.895 | $0.83 | SDA-2026-04-03-gap-a |
| #18 | TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration | TREM2 | 0.892 | $0.77 | SDA-2026-04-03-gap-a |
| #19 | Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.888 | $0.91 | SDA-2026-04-01-gap-2 |
| #20 | Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible | APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis) | 0.887 | $0.81 | SDA-2026-04-12-20260 |
| #21 | TREM2-APOE Axis Dissociation for Selective DAM Activation | TREM2-APOE axis | 0.886 | $0.86 | SDA-2026-04-01-gap-0 |
| #22 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.880 | $0.92 | SDA-2026-04-03-gap-a |
| #23 | Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration | IFNG | 0.879 | $0.87 | SDA-2026-04-16-gap-d |
| #24 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.875 | $0.92 | SDA-2026-04-03-gap-a |
| #25 | TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence | CYP46A1 | 0.869 | $0.89 | SDA-2026-04-03-gap-a |
| #26 | Complement Cascade Inhibition Synaptic Protection | - | 0.867 | $0.81 | SDA-2026-04-16-gap-p |
| #27 | Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-gamma coupling and prevent tau seeding in AD | PVALB | 0.863 | $0.88 | SDA-2026-04-03-26abc |
| #28 | Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization | BDNF | 0.861 | $0.81 | SDA-2026-04-03-26abc |
| #29 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via direct PV interneuron recruitment in Alzheimer's disease | PVALB | 0.858 | $0.98 | SDA-2026-04-03-26abc |
| #30 | TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition | NAMPT | 0.858 | $0.74 | SDA-2026-04-16-gap-d |
| #31 | Senescent Cell ASM-Complement Cascade Intervention | SMPD1 | 0.852 | $0.87 | SDA-2026-04-01-gap-l |
| #32 | Microglial Senescence Prevention via TREM2/SASP Axis | - | 0.847 | $0.78 | SDA-2026-04-16-gap-p |
| #33 | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | TYROBP | 0.844 | $0.72 | SDA-2026-04-01-gap-0 |
| #34 | miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Microglial State Transition | MIR155 | 0.843 | $0.82 | SDA-2026-04-16-gap-d |
| #35 | Gamma Oscillation Enhancement Synergy | - | 0.838 | $0.82 | SDA-2026-04-16-gap-p |
| #36 | Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest | Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) | 0.838 | $0.78 | SDA-2026-04-16-gap-p |
| #37 | Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhythmogenesis and block tau AIS disruption in AD | PVALB | 0.831 | $0.93 | SDA-2026-04-03-26abc |
| #38 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymphatic enhancement and amyloid clearance from PV interneurons in Alzheimer's disease | PVALB | 0.827 | $0.76 | SDA-2026-04-03-26abc |
| #39 | Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal-prefrontal synchrony in early AD | SST | 0.827 | $0.78 | SDA-2026-04-03-26abc |
| #40 | Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD | AIM2, CASP1, IL1B, PYCARD, TARDBP | 0.824 | $0.86 | SDA-2026-04-01-gap-2 |
| #41 | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.822 | $0.72 | SDA-2026-04-01-gap-2 |
| #42 | Ketone Utilization Index as Metabolic Flexibility Biomarker | HMGCS2 | 0.819 | $0.83 | SDA-2026-04-04-gap-d |
| #43 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.814 | $0.73 | SDA-2026-04-04-gap-t |
| #44 | TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance | TREM2 | 0.812 | $0.86 | SDA-2026-04-03-26abc |
| #45 | CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds | APOE, CLU | 0.811 | $0.69 | SDA-2026-04-15-gap-d |
| #46 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.808 | $0.77 | SDA-2026-04-04-gap-t |
| #47 | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | CSF1R-TREM2 | 0.808 | $0.78 | SDA-2026-04-01-gap-0 |
| #48 | P2RX7-Mediated Exosome Secretion Blockade | P2RX7 | 0.807 | $0.78 | SDA-2026-04-04-gap-t |
| #49 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.74 | SDA-2026-04-16-gap-b |
| #50 | Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.805 | $0.78 | SDA-2026-04-01-gap-2 |
| #51 | Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD, PPIF | 0.804 | $0.77 | SDA-2026-04-01-gap-2 |
| #52 | TREM2-mTOR Co-Agonism for Metabolic Reprogramming | TREM2-mTOR pathway | 0.803 | $0.74 | SDA-2026-04-01-gap-0 |
| #53 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.87 | - |
| #54 | Prime Editing Precision Correction of APOE4 to APOE3 in Microglia | APOE | 0.803 | $0.68 | SDA-2026-04-03-gap-c |
| #55 | Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents Both Cytotoxic and Vasogenic Edema After Cardiac Arrest | AQP4 and ACSL4 (key ferroptosis regulator) | 0.803 | $0.75 | SDA-2026-04-16-gap-p |
| #56 | Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.803 | $0.68 | SDA-2026-04-01-gap-2 |
| #57 | 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia | ACSL4 | 0.801 | $0.76 | SDA-2026-04-03-gap-s |
| #58 | TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation | TREM2/TYROBP | 0.800 | $0.72 | SDA-2026-04-06-gap-p |
| #59 | Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector | MANF, CDNF | 0.798 | $0.73 | SDA-2026-04-16-gap-p |
| #60 | Microglial TREM2-SYK Pathway Enhancement | TREM2 | 0.798 | $0.74 | SDA-2026-04-03-gap-s |
| #61 | SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis | HK2/PFKFB3 | 0.796 | $0.94 | sda-2026-04-01-gap-0 |
| #62 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.792 | $0.82 | SDA-2026-04-03-26abc |
| #63 | Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology | CHRNA7 (α7 nicotinic receptor), BACE1 | 0.785 | $0.81 | SDA-2026-04-12-20260 |
| #64 | Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophagy flux and degrade intracellular tau before exosomal packaging in Alzheimer's disease | SST | 0.784 | $0.87 | SDA-2026-04-03-26abc |
| #65 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.780 | $0.67 | SDA-2026-04-04-gap-t |
| #66 | LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia | LPCAT3 | 0.779 | $0.82 | SDA-2026-04-03-gap-s |
| #67 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease | ACSL4 | 0.779 | $0.82 | SDA-2026-04-03-gap-s |
| #68 | ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation | ALOX15 | 0.777 | $0.82 | SDA-2026-04-03-gap-s |
| #69 | CX3CR1-TREM2 Integration for Synapse Pruning Normalization | CX3CR1-TREM2 | 0.776 | $0.76 | SDA-2026-04-01-gap-0 |
| #70 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia | LPCAT3 | 0.776 | $0.67 | SDA-2026-04-03-gap-s |
| #71 | Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway | GPNMB, CD44 | 0.772 | $0.71 | SDA-2026-04-16-gap-p |
| #72 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia | LPCAT3 | 0.770 | $0.66 | SDA-2026-04-03-gap-s |
| #73 | Oligodendrocyte Precursor Cell Senescence in White Matter Disease | CSPG4,OLIG2,BCL2 | 0.769 | $0.73 | SDA-2026-04-04-gap-s |
| #74 | Lysosomal Cathepsin-Dependent Tau Clearance | - | 0.767 | $0.75 | SDA-2026-04-16-gap-p |
| #75 | cGAS-STING Pathway Hyperactivation Mediates Tau Propagation | cGAS (CGAS), STING (TMEM173) | 0.760 | $0.76 | SDA-2026-04-02-gap-2 |
| #76 | INPP5D (SHIP1) Inhibition to Shift Microglial Polarization | INPP5D | 0.758 | $0.74 | SDA-2026-04-01-gap-0 |
| #77 | sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy | - | 0.757 | $0.87 | SDA-2026-04-16-gap-p |
| #78 | Test: TREM2 enhances amyloid clearance | - | 0.755 | $0.70 | - |
| #79 | Dual-Circuit Tau Vulnerability Cascade | MAPT | 0.754 | $0.70 | SDA-2026-04-03-26abc |
| #80 | Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation | TREM2 | 0.750 | $0.75 | SDA-2026-04-04-gap-t |
| #81 | TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming | TREM2, CSF1R | 0.748 | $0.90 | SDA-2026-04-03-gap-a |
| #82 | C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV Interneuron Input Elimination in Alzheimer's Disease | C1QA, C1QB | 0.747 | $0.70 | SDA-2026-04-15-gap-d |
| #83 | TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging | TREM2 | 0.744 | $0.90 | SDA-2026-04-03-gap-a |
| #84 | miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy | miR-33/ABCA1 | 0.741 | $0.69 | SDA-2026-04-16-gap-d |
| #85 | TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid Sensing and Clearance Deficits | TREM2, APOE | 0.741 | $0.62 | SDA-2026-04-02-gap-0 |
| #86 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impairment | MAPT | 0.737 | $0.76 | SDA-2026-04-03-26abc |
| #87 | Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Phase | TREM2, APOE, MAPT | 0.735 | $0.72 | SDA-2026-04-02-gap-0 |
| #88 | Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis) | SIRT3/NAD+ salvage pathway, PGC-1α | 0.735 | $0.65 | SDA-2026-04-06-gap-d |
| #89 | Selective Neutral Sphingomyelinase-2 Inhibition Therapy | SMPD3 | 0.731 | $0.85 | SDA-2026-04-01-gap-l |
| #90 | TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome | TREM2/DAP12 (TYROBP) | 0.730 | $0.73 | SDA-2026-04-06-gap-p |
| #91 | Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin | CHI3L1/TREM2/NRGN | 0.730 | $0.73 | SDA-2026-04-06-gap-d |
| #92 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.728 | $0.76 | SDA-2026-04-15-gap-p |
| #93 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.75 | SDA-2026-04-03-gap-s |
| #94 | Differential Complement Regulator Expression on Synaptic Membranes (CD55/CD46) | CD55 (DAF), CD46 (MCP) | 0.725 | $0.73 | SDA-2026-04-07-gap-p |
| #95 | Excessive C1q/C3/CR3 complement cascade activation initiates pre-symptomatic synaptic loss in Alzheimer's disease | C1QA, C1QB, C1QC, C3, ITGAM/ITGAX | 0.720 | $0.72 | SDA-2026-04-02-gap-s |
| #96 | SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/MMP-3 Ratio | CXCL1, CXCL2, MMP3 | 0.720 | $0.72 | SDA-2026-04-06-gap-d |
| #97 | Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification | IFNAR1/IFNAR2, STING (TMEM173), cGAS (CGAS) | 0.720 | $0.72 | SDA-2026-04-07-gap-p |
| #98 | AAV-PHP.eB-Mediated Microglial IGFBPL1 Expression | IGFBPL1 | 0.720 | $0.72 | SDA-2026-04-06-gap-d |
| #99 | NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype | NLRP3/CASP1/IL1B | 0.720 | $0.72 | SDA-2026-04-06-gap-p |
| #100 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.718 | $0.67 | SDA-2026-04-03-gap-s |
| #101 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial Metabolic Fitness | TREM2, TYROBP, SYK, PI3K | 0.718 | $0.70 | SDA-2026-04-02-gap-0 |
| #102 | Vascular-Glial Interface Restoration | CLDN5 | 0.716 | $0.74 | SDA-2026-04-03-gap-s |
| #103 | Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Inflammation | TREM2, ADAM10, ADAM17 | 0.714 | $0.70 | SDA-2026-04-02-gap-0 |
| #104 | Test: TREM2 enhances amyloid clearance | - | 0.712 | $0.70 | - |
| #105 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.66 | SDA-2026-04-03-gap-a |
| #106 | APOE4-Specific Microglial Metabolic Rescue | APOE, ABCA1, LDLR | 0.710 | $0.74 | SDA-2026-04-04-gap-n |
| #107 | Regional TREM2-Dependent Lipid Metabolism Determines Cortical Vulnerability in Alzheimer's Disease | TREM2 | 0.710 | $0.71 | SDA-2026-04-06-gap-p |
| #108 | CSF YKL-40 as a Priming-Specific Chitinase Marker | CHI3L1/YKL-40 | 0.710 | $0.71 | SDA-2026-04-06-gap-d |
| #109 | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroinflammation | APOE | 0.710 | $0.71 | SDA-2026-04-02-gap-s |
| #110 | TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative | TREM2 | 0.708 | $0.71 | SDA-2026-04-07-gap-p |
| #111 | Creatine Kinase System Capacity as Neural Energy Reserve Biomarker | CKB | 0.707 | $0.70 | SDA-2026-04-04-gap-d |
| #112 | Autophagy-Lysosomal Degradation of IBA1 in Stressed Microglia | LC3/P62/SQSTM1 | 0.706 | $0.71 | SDA-2026-04-07-gap-p |
| #113 | Test: TREM2 enhances amyloid clearance | - | 0.705 | $0.70 | - |
| #114 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.73 | SDA-2026-04-03-gap-a |
| #115 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | SOD1, TARDBP, BDNF, GDNF, IGF-1 | 0.704 | $0.74 | SDA-2026-04-03-gap-c |
| #116 | Microglial Exosome-Mediated Tau Propagation | MAPT | 0.702 | $0.67 | SDA-2026-04-03-26abc |
| #117 | DAMP-Scavenging Microglial Reset | HMGB1, S100 proteins | 0.701 | $0.73 | SDA-2026-04-04-gap-n |
| #118 | TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switching from protective 'disease-associated microglia' to neurotoxic 'inflammasome-active' states | TREM2, TYROBP (DAP12), APOE | 0.700 | $0.70 | SDA-2026-04-02-gap-s |
| #119 | NAD+ Decline and SIRT1 Deficiency Drive Epigenetic Reprogramming Toward Senescence | SIRT1/NAMPT/PPARGC1A | 0.700 | $0.70 | SDA-2026-04-06-gap-p |
| #120 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | 0.700 | $0.70 | sda-2026-04-01-gap-2 |
| #121 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack | GZMB | 0.698 | $0.73 | SDA-2026-04-15-gap-d |
| #122 | Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated Amplification | MAPT | 0.696 | $0.73 | SDA-2026-04-03-26abc |
| #123 | Temporal Microglial State Switching | Optogenetic constructs, ion channels | 0.695 | $0.73 | SDA-2026-04-04-gap-n |
| #124 | Peripheral Monocyte/Macrophage Infiltration Mimicking Microglial Loss | CCR2 | 0.693 | $0.69 | SDA-2026-04-07-gap-p |
| #125 | TREM2-Dependent Microglial Surveillance Controls AQP4-Mediated Tau Clearance Through Astrocytic Endfoot Maintenance | TREM2 | 0.691 | $0.74 | SDA-2026-04-03-26abc |
| #126 | TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocyte Tau Clearance Networks | TREM2 | 0.691 | $0.74 | SDA-2026-04-03-26abc |
| #127 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.72 | SDA-2026-04-03-gap-a |
| #128 | H5: BET Bromodomain Readers Sense Aberrant Chromatin and Drive Neuroinflammatory Transcription | BRD4, BET bromodomains (BRD2/3/4) | 0.690 | $0.69 | SDA-2026-04-04-gap-2 |
| #129 | TREM2-Dependent Microglial State Transition as Therapeutic Window in Alzheimer's Disease | TREM2, SYK signaling pathway | 0.690 | $0.69 | SDA-2026-04-02-gap-2 |
| #130 | Rab27A/B-mediated exosomal tau secretion from microglia drives frontal cortex propagation at Braak III-VI | RAB27A | 0.690 | $0.69 | SDA-2026-04-07-gap-d |
| #131 | TREM2 Agonism to Rescue APOE4-Induced Microglial Dysfunction | TREM2 | 0.690 | $0.69 | SDA-2026-04-02-gap-a |
| #132 | Endothelial NRF2 Activation as a Master Switch for Post-CA BBB Protection | NRF2 (NFE2L2) in brain microvascular endothelial cells | 0.689 | $0.81 | SDA-2026-04-16-gap-p |
| #133 | Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles | APOE4 | 0.682 | $0.70 | SDA-2026-04-03-gap-d |
| #134 | AQP4 Dysregulation Promotes Neuroinflammation Through Impaired CNS-Peripheral Immune Interface Function | AQP4; IL6R; CD46 (complement) | 0.680 | $0.68 | SDA-2026-04-07-gap-p |
| #135 | Glial Neuroinflammatory Amplification by TDP-43 Pathology | TARDBP | 0.680 | $0.68 | SDA-2026-04-08-gap-p |
| #136 | CSF Soluble TREM2 Fragment Ratio as Priming State Indicator | TREM2/ADAM10/17 | 0.680 | $0.68 | SDA-2026-04-06-gap-d |
| #137 | Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker | SLC16A1 | 0.677 | $0.67 | SDA-2026-04-04-gap-d |
| #138 | Cell-Type Specific TFEB Modulation | TFEB | 0.677 | $0.70 | SDA-2026-04-03-gap-d |
| #139 | Astrocyte-Mediated Microglial Memory Erasure | GFAP, S100B | 0.677 | $0.71 | SDA-2026-04-04-gap-n |
| #140 | Microglial TREM2-Mediated Tau Phagocytosis Impairment | MAPT | 0.676 | $0.72 | SDA-2026-04-03-26abc |
| #141 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | CXCL10 | 0.675 | $0.70 | SDA-2026-04-03-gap-a |
| #142 | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.672 | $0.72 | SDA-2026-04-03-26abc |
| #143 | Microglial P2Y12-Dependent Territorial Segregation of Synaptic Inputs | P2RY12 (P2Y12 receptor) | 0.670 | $0.67 | SDA-2026-04-07-gap-p |
| #144 | TREM2 R47H variant synergizes with APOE4 to collapse microglial lipid clearance capacity, causing extracellular lipid accumulation that feeds back to astrocyte lipid droplet formation | TREM2, APOE | 0.670 | $0.67 | SDA-2026-04-04-gap-a |
| #145 | LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes at complement gene loci, driving hyperactive synaptic pruning in late-life neurodegeneration | NLRP3, H3K4me3 writers (MLL3/4, SETD1A), H3K27ac (EP300/CREBBP) | 0.670 | $0.67 | SDA-2026-04-02-gap-s |
| #146 | TREM2 Agonism Has Narrow Early-Window at DAM1→DAM2 Transition Checkpoint | TREM2, SYK signaling axis | 0.668 | $0.67 | SDA-2026-04-06-gap-d |
| #147 | White Matter Vulnerability Prevention via Oligodendrocyte Protection | CXCL10 | 0.667 | $0.70 | SDA-2026-04-03-gap-a |
| #148 | Oligodendrocyte DNA Repair Enhancement Therapy | PARP1 and XRCC1 | 0.665 | $0.70 | SDA-2026-04-03-gap-s |
| #149 | Peripheral-Central Immune Decoupling Therapy | TREM2, complement cascade components | 0.662 | $0.69 | SDA-2026-04-04-gap-n |
| #150 | Circadian-Metabolic Microglial Reprogramming | CLOCK, BMAL1, PER2 | 0.662 | $0.69 | SDA-2026-04-04-gap-n |
| #151 | BBB Integrity Loss Defines Absolute Therapeutic Window Closure | MMP-9, Claudin-5, PDGFRβ (pericyte coverage) | 0.660 | $0.66 | SDA-2026-04-06-gap-d |
| #152 | Astrocyte IL-1β as Paracrine Mediator of Microglial Complement Expression | IL1B; IL1R1; MYD88 | 0.660 | $0.66 | SDA-2026-04-08-gap-p |
| #153 | Focused Ultrasound with Microbubble Contrast Agents | IGFBPL1 | 0.660 | $0.66 | SDA-2026-04-06-gap-d |
| #154 | Test: TREM2 enhances amyloid clearance | - | 0.655 | $0.66 | - |
| #155 | Astrocyte-Microglia Communication Rebalancing via Cytokine Modulation | IL1A, TNF, C1Q | 0.655 | $0.69 | SDA-2026-04-03-gap-d |
| #156 | Microbiota-Microglia Axis Modulation | Multiple | 0.651 | $0.68 | SDA-2026-04-04-gap-2 |
| #157 | Astrocyte APOE4-Specific Lipid Metabolism Correction | APOE | 0.651 | $0.69 | SDA-2026-04-03-gap-s |
| #158 | NRF2-KEAP1 Pathway Activation to Coordinate Multi-Layer Antioxidant Defense | NRF2 (NFE2L2), KEAP1 | 0.650 | $0.62 | SDA-2026-04-16-gap-f |
| #159 | Loss of Homeostatic Epigenetic Identity Reprograms Microglia to Dystrophic State | EZH2/DNMT1/DNMT3A/P2RY12/TMEM119 | 0.650 | $0.65 | SDA-2026-04-06-gap-p |
| #160 | TNF-α/NF-κB Axis Upregulates P2RY12 in VSMCs | RELA (p65), IKBKB (IKKβ) | 0.650 | $0.65 | SDA-2026-04-07-gap-p |
| #161 | Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysosomal membrane permeabilization | LGALS3 | 0.650 | $0.65 | SDA-2026-04-04-gap-l |
| #162 | TREM2-Mediated Oligodendrocyte-Microglia Metabolic Coupling in White Matter Neurodegeneration | TREM2 | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #163 | Age-Dependent TREM2 Signaling Disrupts Astrocyte-Microglia Communication Leading to Senescent Glial Networks | TREM2 | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #164 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | TREM2 | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #165 | APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration | APOE | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #166 | CLU-APOE-TREM2 Tripartite Axis as a Coordinate Therapeutic Target | CLU-APOE-TREM2 axis (LXR/RXR pathway) | 0.648 | $0.64 | SDA-2026-04-14-gap-p |
| #167 | Epigenetic Reprogramming of Microglial Memory | DNMT3A, HDAC1/2 | 0.647 | $0.68 | SDA-2026-04-04-gap-2 |
| #168 | Inflammatory State-Dependent Ketone Timing | IRAKM | 0.647 | $0.64 | SDA-2026-04-03-gap-d |
| #169 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.646 | $0.67 | SDA-2026-04-03-gap-i |
| #170 | Oligodendrocyte Remyelination Enhancement | TREM2 | 0.644 | $0.67 | SDA-2026-04-03-gap-a |
| #171 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.63 | SDA-2026-04-15-gap-p |
| #172 | White Matter Immune Checkpoint Restoration | CXCL10 | 0.644 | $0.68 | SDA-2026-04-03-gap-a |
| #173 | Cell-Type Specific Metabolic Reprogramming | PPARA | 0.643 | $0.68 | SDA-2026-04-03-gap-s |
| #174 | Epigenetic Silencing of AIF1 Gene Locus by Chronic Inflammation | DNMT1/DNMT3A | 0.643 | $0.64 | SDA-2026-04-07-gap-p |
| #175 | TREM2-Driven Senescence Biomarker Index for Predicting Neurodegeneration Risk | TREM2 | 0.642 | $0.64 | SDA-2026-04-03-gap-a |
| #176 | CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk | CX3CR1 | 0.640 | $0.64 | SDA-2026-04-07-gap-d |
| #177 | Heterogeneous astrocyte activation states differentially impact neuronal survival across AD progression | GFAP | 0.640 | $0.68 | SDA-2026-04-04-analy |
| #178 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.67 | SDA-2026-04-03-gap-c |
| #179 | Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase | TREM2 | 0.637 | $0.62 | SDA-2026-04-02-gap-0 |
| #180 | Test: TREM2 enhances amyloid clearance | - | 0.637 | $0.64 | - |
| #181 | Vascular mural cell degeneration precedes and exacerbates parenchymal pathology | PDGFRB | 0.637 | $0.66 | SDA-2026-04-04-analy |
| #182 | Astrocyte Metabolic Reprogramming via APOE4 Correction | APOE | 0.636 | $0.67 | SDA-2026-04-03-gap-s |
| #183 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.62 | SDA-2026-04-15-gap-d |
| #184 | Liver-Derived Inflammatory Suppressors Downregulate Microglial IBA1 | STAT3/JAK1 | 0.633 | $0.63 | SDA-2026-04-07-gap-p |
| #185 | TREM2 R47H Variant Correction — AAV-Mediated Rescue of Common Risk Allele | TREM2 | 0.631 | $0.61 | SDA-2026-04-02-gap-0 |
| #186 | Intestinal Permeability Defects → Systemic LPS Translocation → Microglial Priming | Tight junction complex (CLDN1, OCLN, TJP1), LBP, CD14, TLR4, MYD88, NFKB1 | 0.630 | $0.63 | sda-2026-04-01-gap-2 |
| #187 | CX3CR1 Agonism Enhances Microglial Phagocytosis of Extracellular Tau Seeds, Preventing Template-Dependent Misfolding | CX3CR1 | 0.630 | $0.63 | SDA-2026-04-04-gap-2 |
| #188 | Epigenetic Bivalency at CDKN2A Locus Distinguishes Senescent from Activated Microglia | CDKN2A, H3K9me3, DREAM complex (LIN9, LIN37, RBL2) | 0.630 | $0.63 | SDA-2026-04-06-gap-d |
| #189 | Selective Cholinergic Protection via APP Pathway Modulation | APP | 0.629 | $0.66 | SDA-2026-04-03-gap-a |
| #190 | Gut-Brain Axis M-Cell Modulation | GP2, SPIB | 0.629 | $0.66 | SDA-2026-04-04-gap-n |
| #191 | TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification | TREM2 | 0.628 | $0.61 | SDA-2026-04-02-gap-0 |
| #192 | Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's disease | TREM2 | 0.628 | $0.67 | SDA-2026-04-04-analy |
| #193 | TREM2 Super-Agonist Induction of DAM Program | - | 0.627 | $0.63 | SDA-2026-04-16-gap-2 |
| #194 | Cardiovascular-Neuroinflammatory Dual Targeting | TNF/IL6 | 0.627 | $0.66 | SDA-2026-04-04-gap-2 |
| #195 | Peripheral-to-Central Inflammation Circuit Breaker | IL1B | 0.626 | $0.67 | SDA-2026-04-16-gap-b |
| #196 | Microglial TREM2-Independent Pathway Activation | DAP12, SYK, PLCG2 | 0.623 | $0.66 | SDA-2026-04-03-gap-d |
| #197 | Microglial ACE Enhancement for Amyloid Clearance | ACE | 0.622 | $0.65 | SDA-2026-04-03-gap-a |
| #198 | Tau fibrils expose neuronal phosphatidylserine and heat-shock protein 70, driving microglial non-complement synaptic engulfment in primary tauopathies | Phosphatidylserine, TIMD4, HSPA1A/HSPA1B, SCARF1, LRP8 | 0.620 | $0.62 | SDA-2026-04-02-gap-s |
| #199 | Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Cell-Autonomous Glutamate Toxicity | SLC7A11 | 0.620 | $0.60 | SDA-2026-04-16-gap-f |
| #200 | Cross-Cell Type Synaptic Rescue via Tripartite Synapse Restoration | SYN1, SLC1A2, and CX3CR1 | 0.620 | $0.65 | SDA-2026-04-03-gap-s |
| #201 | Metabolic Rewiring via SPP1-Induced HIF1α Glycolytic Shift | HIF1A (HIF1α), MTOR (mTORC1), EGLN1 (PHD2) | 0.620 | $0.62 | SDA-2026-04-06-gap-p |
| #202 | CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delivery | HDAC3 (class I histone deacetylase) | 0.620 | $0.62 | SDA-2026-04-08-gap-d |
| #203 | Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis | MTOR/HIF1α | 0.620 | $0.62 | SDA-2026-04-07-gap-d |
| #204 | Complement Cascade Specificity: Microglial C3aR Antagonism Downstream of SPP1 | C3/C3aR | 0.618 | $0.62 | SDA-2026-04-07-gap-p |
| #205 | PDGF-BB/PDGFRβ/STAT3 Paracrine Signaling Axis Mediates Aβ-Induced SPP1 Upregulation | SPP1 | 0.618 | $0.62 | SDA-2026-04-06-gap-p |
| #206 | LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP1 Induction | SPP1 | 0.617 | $0.62 | SDA-2026-04-06-gap-p |
| #207 | Spatially-Targeted Regional Vulnerability Prevention | Regional vulnerability genes | 0.616 | $0.65 | SDA-2026-04-03-gap-s |
| #208 | Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows | TFEB, MAPK14, MAPKAPK2, IL6, CXCL1 | 0.614 | $0.61 | SDA-2026-04-07-gap-d |
| #209 | Test: TREM2 enhances amyloid clearance | - | 0.612 | $0.61 | - |
| #210 | Synaptic Pruning Precision Therapy | C1QA, C3, CX3CR1, CX3CL1 | 0.612 | $0.65 | SDA-2026-04-04-gap-2 |
| #211 | H2: Perforant Path Synapse Loss via Early Complement Cascade Activation | C1QA, C1QB, C3, ITGAM | 0.610 | $0.61 | SDA-2026-04-02-gap-e |
| #212 | Age-Accelerated miR-155 Upregulation Primes Nigral Microglia for Parkinson's Disease Pathology | miR-155 | 0.610 | $0.61 | SDA-2026-04-06-gap-p |
| #213 | Female microglia exhibit heightened complement gene expression and pruning capacity via estrogen-regulated epigenetic sensitization, explaining the female AD risk advantage | ESR2 (NR3A2), KDM6A (UTX), C1QA, C1QB, NFKB1 | 0.610 | $0.61 | SDA-2026-04-02-gap-s |
| #214 | HIF1A stabilization lowers the activation threshold of circadian-disrupted microglia | HIF1A | 0.609 | $0.61 | SDA-2026-04-07-gap-d |
| #215 | Microglial priming is primarily epigenetic, with metabolic changes acting as coupled consequences or cofactors | KDM6B | 0.609 | $0.61 | SDA-2026-04-07-gap-d |
| #216 | P2RY12-mediated autophagy inhibition in cerebral VSMCs impairs CAA clearance | P2RY12 | 0.605 | $0.60 | SDA-2026-04-07-gap-p |
| #217 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.59 | SDA-2026-04-14-gap-p |
| #218 | mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence | MTOR/TFEB/TFE3 | 0.600 | $0.60 | SDA-2026-04-06-gap-p |
| #219 | TREM2-Mediated Oligodendrocyte-Microglia Cross-talk in White Matter Neurodegeneration | TREM2 | 0.600 | $0.60 | SDA-2026-04-03-gap-a |
| #220 | APOE4 Induces Region-Specific Microglial Senescence Driving Frontal Cortex Neurodegeneration | APOE4 | 0.600 | $0.60 | SDA-2026-04-06-gap-p |
| #221 | TREM2-Dependent Senescent Microglia Disrupt Astrocyte Communication Networks | TREM2/TYROBP | 0.600 | $0.54 | SDA-2026-04-03-gap-a |
| #222 | TREM2-Mediated Astroglial Reactivity in Neurodegeneration | TREM2 | 0.600 | $0.60 | SDA-2026-04-03-gap-a |
| #223 | Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therapy | CST, GAL3ST1 | 0.599 | $0.63 | SDA-2026-04-03-gap-d |
| #224 | OPC differentiation blockade contributes to white matter degeneration in early-stage AD | PDGFRA | 0.599 | $0.65 | SDA-2026-04-04-analy |
| #225 | Neuronal MHC Class I Expression as a Selectivity Determinant | H2-Kb (H2-K1), Lilrb4 (LilrB2) | 0.590 | $0.59 | SDA-2026-04-07-gap-p |
| #226 | Cardiovascular-Neuroinflammation Crosstalk Interruption | IL1B, TNFA, NLRP3 | 0.587 | $0.62 | SDA-2026-04-04-gap-2 |
| #227 | TREM2-Mediated Oligodendrocyte-Microglia Signaling in White Matter Neurodegeneration | TREM2 | 0.587 | $0.53 | SDA-2026-04-03-gap-a |
| #228 | Senescence-Tau Decoupling Therapy | CDKN2A | 0.585 | $0.62 | SDA-2026-04-03-gap-a |
| #229 | Gut-Brain Axis Microbiome Modulation | GPR43, GPR109A | 0.585 | $0.62 | SDA-2026-04-04-gap-2 |
| #230 | P2RY12-driven autophagy impairment in cerebral VSMCs mediates BBB breakdown and neurovascular unit dysfunction | P2RY12 | 0.585 | $0.58 | SDA-2026-04-07-gap-p |
| #231 | APOE4 Creates Accelerated, Compressed Reversibility Window | APOE/TREM2 axis, APOE-TREM2 physical interaction | 0.584 | $0.58 | SDA-2026-04-06-gap-d |
| #232 | IGFBPL1-Mediated Homeostatic Restoration | IGFBPL1 | 0.584 | $0.62 | SDA-2026-04-04-gap-2 |
| #233 | Pharmacological P2RY12 inhibition (ticagrelor/clopidogrel) as repurposing probe for neurovascular outcomes | P2RY12 | 0.583 | $0.58 | SDA-2026-04-07-gap-p |
| #234 | Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targeted Neuromodulation | - | 0.583 | $0.57 | SDA-2026-04-16-gap-p |
| #235 | ITGAM/CD11b direct binding explains microglial phagocytosis blockade | ITGAM | 0.582 | $0.58 | SDA-2026-04-21-gap-d |
| #236 | TREM2-Driven Phagocytic Receptor Cascades Determine Mitochondrial Antigen Presentation vs. Intracellular Mitophagy | TREM2 | 0.580 | $0.58 | SDA-2026-04-08-gap-p |
| #237 | Microglial Priming via NF-κB-Dependent DAM Phenotype and Complement Biosynthesis | NFKB1; IKBKB; C1QA; C3 | 0.580 | $0.58 | SDA-2026-04-08-gap-p |
| #238 | TREM2 Promoter Silencing via DNA Hypermethylation | TREM2 | 0.580 | $0.58 | SDA-2026-04-07-gap-d |
| #239 | Microglial Replacement and Ontogeny Shift | CCR2 | 0.580 | $0.58 | SDA-2026-04-07-gap-d |
| #240 | Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Through Attenuated Chemotaxis | P2RY12 | 0.580 | $0.58 | SDA-2026-04-06-gap-p |
| #241 | Neuroinflammation-Driven TDP-43 Mislocalization via Microglial APOE4 Signaling | NLRP3, LRP1, IL1B, TNF | 0.580 | $0.58 | SDA-2026-04-07-gap-p |
| #242 | αvβ3 Integrin-FAK-SYK-CARD9/NF-κB Pathway | ITGAV/ITGB3 (αvβ3 heterodimer), PTK2 (FAK), SYK, CARD9 | 0.580 | $0.58 | SDA-2026-04-06-gap-p |
| #243 | Complement-Mediated Synaptic Protection | C1QA | 0.580 | $0.62 | SDA-2026-04-04-gap-2 |
| #244 | IGFBPL1-Mediated Microglial Reprogramming | IGFBPL1 | 0.579 | $0.62 | SDA-2026-04-04-gap-2 |
| #245 | TREM2-Astrocyte Communication in Microglial Dysfunction | TREM2 | 0.579 | $0.00 | SDA-2026-04-03-gap-a |
| #246 | Dynamic Microglial Phenotype Switching Biomarker Panel for Neuroinflammatory Treatment Stratification | TREM2 | 0.577 | $0.58 | SDA-2026-04-16-gap-p |
| #247 | TREM2-Senescence Cascade in Astrocyte-Microglia Communication Breakdown | TREM2 | 0.574 | $0.00 | SDA-2026-04-03-gap-a |
| #248 | TREM2-P2RY12 Balance Restoration Therapy | TREM2 | 0.571 | $0.61 | SDA-2026-04-04-gap-2 |
| #249 | Disease-Associated Microglia (DAM) Program Drives IBA1 Downregulation | TREM2/TYROBP | 0.571 | $0.57 | SDA-2026-04-07-gap-p |
| #250 | PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control | PINK1 | 0.571 | $0.57 | SDA-2026-04-03-gap-i |
| #251 | Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization | SNCA | 0.571 | $0.60 | SDA-2026-04-03-gap-d |
| #252 | CX3CR1-Negative Trem2-High Microglial Subset Mediates Female Resilience via Estrogen Receptor-alpha Suppression of NLRP3 | ESR1 | 0.570 | $0.57 | SDA-2026-04-06-gap-p |
| #253 | Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition | HDAC6 (class IIb histone deacetylase) | 0.570 | $0.57 | SDA-2026-04-08-gap-d |
| #254 | Direct NF-κB Transcriptional Regulation of C1q Genes in Microglia | RELA; C1QA/C1QB/C1QC | 0.570 | $0.57 | SDA-2026-04-08-gap-p |
| #255 | Temporal Gating of Microglial Responses | CLOCK, ARNTL | 0.565 | $0.63 | SDA-2026-04-04-gap-2 |
| #256 | Closed-loop transcranial focused ultrasound targeting entorhinal PV interneurons to restore AnkyrinG-dependent AIS integrity and hippocampal gamma synchrony in Alzheimer's disease | PVALB | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #257 | Closed-loop tACS targeting EC-II somatostatin interneurons to restore dendritic integration and prevent tau-mediated HCN channel dysfunction in AD | SST | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #258 | Persistent γH2AX+53BP1 Foci with DREAM Complex Activation Defines Irreversibly Arrested Microglia | H2AFX (γH2AX), TP53BP1, DREAM complex (LIN9, LIN37, RBL2, E2F4) | 0.560 | $0.56 | SDA-2026-04-06-gap-d |
| #259 | P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming | P2RX7/NLRP3 | 0.560 | $0.56 | SDA-2026-04-06-gap-d |
| #260 | Test: TREM2 enhances amyloid clearance | - | 0.555 | $0.55 | - |
| #261 | GluN2B-Mediated Microglial Activation and Tau Propagation | GRIN2B | 0.555 | $0.56 | SDA-2026-04-03-26abc |
| #262 | Inhibitory Neuron-Selective WNT Signaling Restoration | WNT3A, CTNNB1, TCF7L2 | 0.554 | $0.62 | SDA-2026-04-03-gap-d |
| #263 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.60 | SDA-2026-04-03-gap-a |
| #264 | Dual NF-κB/MMP Inhibition Strategy | NFKB1 | 0.554 | $0.57 | SDA-2026-04-16-gap-b |
| #265 | Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows | NLRP3 | 0.551 | $0.55 | SDA-2026-04-15-gap-p |
| #266 | Astrocytic SPP1 Modulation Through STAT3-Dependent Transcriptional Control | SPP1 | 0.551 | $0.55 | SDA-2026-04-15-gap-p |
| #267 | oxLDL/LOX-1/ROS Signaling Induces P2RY12 via Nrf2 Activation | OLR1 (LOX-1), NFE2L2 (Nrf2) | 0.550 | $0.55 | SDA-2026-04-07-gap-p |
| #268 | Surface Exposure of SENP1-β1 Integrin Complex Enables Targeted Senolytic Elimination | SENP1, ITGB1 (β1 integrin), ITGAM (CD11b) | 0.550 | $0.55 | SDA-2026-04-06-gap-d |
| #269 | Oligodendrocyte DNA Repair Enhancement | PARP1 | 0.550 | $0.59 | SDA-2026-04-03-gap-s |
| #270 | Perinatal Hypoxia-Primed Microglia Targeting | HIF1A, NFKB1 | 0.548 | $0.59 | SDA-2026-04-04-gap-2 |
| #271 | CD300f Immune Checkpoint Activation | CD300F | 0.545 | $0.61 | SDA-2026-04-03-gap-a |
| #272 | TREM2-GluN2B Circuit: Microglial Control of Thalamocortical Oscillations and Glymphatic Tau Clearance | TREM2 | 0.543 | $0.00 | SDA-2026-04-03-26abc |
| #273 | Epigenetic Reprogramming Required for Late-Stage Interventions (OSKM) | DNA methylation machinery (DNMTs), H3K27ac modifiers (p300/CBP, HDACs) | 0.542 | $0.54 | SDA-2026-04-06-gap-d |
| #274 | TAM Receptor (MERTK/AXL) Cross-Regulation | MERTK, AXL, TYRO3, PROS1 (Protein S), GAS6 | 0.540 | $0.54 | SDA-2026-04-06-gap-p |
| #275 | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and exosomal re-secretion in mid-to-late disease | P2RY6 | 0.540 | $0.54 | SDA-2026-04-07-gap-d |
| #276 | Synaptic Vulnerability Window Temporal Targeting: Transient SPP1 Blockade | SPP1 | 0.540 | $0.54 | SDA-2026-04-07-gap-p |
| #277 | H5: Olfactory System as a Toxicant Funnel into Layer II | NLRP3, CX3CR1, TLR4 | 0.540 | $0.54 | SDA-2026-04-02-gap-e |
| #278 | Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, removing the neuronal 'don't eat me' signal from microglial CX3CR1 | CX3CL1, CX3CR1, ADAM10, ADAM17 | 0.540 | $0.54 | SDA-2026-04-02-gap-s |
| #279 | Test: TREM2 enhances amyloid clearance | - | 0.537 | $0.54 | - |
| #280 | CD36 Acts as Primary Aβ Oligomer Sensor on Perivascular Macrophages, Triggering NF-κB-Dependent SPP1 Transcription | SPP1 | 0.535 | $0.74 | SDA-2026-04-06-gap-p |
| #281 | NFκB/C1Q SASP Modulation for Synaptic Protection | - | 0.534 | $0.53 | SDA-2026-04-16-gap-p |
| #282 | TREM2-Mediated Microglial Checkpoint Therapy | TREM2 | 0.534 | $0.58 | SDA-2026-04-03-gap-s |
| #283 | TSPO PET Kinetic Modeling for Priming State Discrimination | TSPO | 0.530 | $0.53 | SDA-2026-04-06-gap-d |
| #284 | CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal | MIR155 (microRNA-155) | 0.530 | $0.53 | SDA-2026-04-08-gap-d |
| #285 | TREM2 Epigenetic Window for Microglial Lipid Metabolism | TREM2/HDAC1 | 0.525 | $0.53 | SDA-2026-04-07-gap-d |
| #286 | TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance | TREM2 | 0.524 | $0.00 | SDA-2026-04-03-26abc |
| #287 | TREM2 Agonism to Redirect Microglia from Synaptic Pruning to OPTN-Deficient Neuron Protection | TREM2 | 0.521 | $0.51 | SDA-2026-04-14-gap-p |
| #288 | M-Sec/TNTA2-mediated tunneling nanotube formation drives glia-neuron tau propagation in mid-stages | TNFAIP2 | 0.520 | $0.52 | SDA-2026-04-07-gap-d |
| #289 | Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming | Epigenetic landscape (TLR4, NLRP3, IL1B regulatory regions) | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #290 | Dysregulated microglial glycolysis via HIF1α activation shifts the balance from neuroprotective surveillance to complement-mediated synapse engulfment | HIF1A, LDHA, LDHB, PKM2, TREM2, AMPK/mTOR | 0.520 | $0.52 | SDA-2026-04-02-gap-s |
| #291 | Loss of Nuclear Lamin B1 Distinguishes Senescent Microglia from Inflammatory Activation | LMNB1 (Lamin B1) | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #292 | Mitochondrial DNA Damage and cGAS-STING Activation Induces Microglial Senescence | CGAS/STING1/TMEM173 | 0.520 | $0.52 | SDA-2026-04-06-gap-p |
| #293 | GATA4 Stabilization and NF-κB Co-activation Identifies Senescent Microglia | GATA4, SQSTM1/p62, NFKB subunits | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #294 | Telomere Attrition and DNA Damage Response Activation Induces Microglial Senescence | TP53/CDKN2A/CDKN1A/ATM/ATR | 0.520 | $0.52 | SDA-2026-04-06-gap-p |
| #295 | Epigenetic Dysregulation of APOE Microglial Expression | APOE | 0.520 | $0.52 | SDA-2026-04-07-gap-d |
| #296 | miR-143/145 Cluster Dysregulation Derepresses P2RY12 Transcription | MIR143, MIR145, KLF4 | 0.520 | $0.52 | SDA-2026-04-07-gap-p |
| #297 | Severely Depleted mtDNA and Impaired OXPHOS Defines Senescent Microglia | MT-ND1, MT-CO1, TFAM, SIRT3 | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #298 | Lipid Nanoparticle Encapsulation of IGFBPL1-mRNA | IGFBPL1 | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #299 | Downstream Pathway Selective Modulation: ITGAX (αXβ2) Integrin Blockade | ITGAX (CD11c) | 0.519 | $0.52 | SDA-2026-04-07-gap-p |
| #300 | Stage-Dependent Biphasic SPP1 Targeting: Early Enhancement Followed by Late Inhibition | SPP1 | 0.518 | $0.52 | SDA-2026-04-07-gap-p |
| #301 | NRF2 Activation to Counteract Oxidative Stress from RGS6 Deficiency | - | 0.518 | $0.52 | SDA-2026-04-17-gap-p |
| #302 | Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2 | NRF2/NFE2L2 | 0.517 | $0.52 | SDA-2026-04-07-gap-p |
| #303 | Hippocampus ages transcriptionally faster than cerebellum, defining a regional vulnerability axis conserved across species | CLU | 0.516 | $0.50 | aging-mouse-brain-20 |
| #304 | Test: TREM2 enhances amyloid clearance | - | 0.512 | $0.51 | - |
| #305 | Tripartite Synapse Cell Type-Nonautonomous Crosstalk: Coordinated Failure | C1Q | 0.510 | $0.51 | SDA-2026-04-02-gap-s |
| #306 | Primed microglia occupy a hybrid high-glycolysis and high-respiration metabolic state | PDHA1 | 0.510 | $0.51 | SDA-2026-04-07-gap-d |
| #307 | Circulating IBA1 Protein Absorption/Interference with Detection | AIF1/IBA1 | 0.507 | $0.51 | SDA-2026-04-07-gap-p |
| #308 | PKM2 nuclear translocation bridges metabolism and inflammatory transcription in primed microglia | PKM2 | 0.506 | $0.51 | SDA-2026-04-07-gap-d |
| #309 | CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping | CX3CR1 | 0.500 | $0.50 | SDA-2026-04-06-gap-d |
| #310 | LRP1 Loss-of-Function Derepresses P2RY12 Expression | LRP1 | 0.500 | $0.50 | SDA-2026-04-07-gap-p |
| #311 | Selectively Inhibit Maladaptive AQP4-Driven Astrocyte-Microglia Inflammatory Signaling in Parkinsonian Injury | AQP4, NFKB1, IL1B, TNF | 0.500 | $0.50 | SDA-2026-04-07-gap-p |
| #312 | Early Postnatal TGF-beta Signaling Establishes Lifelong Regional Vulnerability Through Irreversible Transcriptional Imprinting | TGFBR1 | 0.500 | $0.50 | SDA-2026-04-06-gap-p |
| #313 | Alectinib-C1q Complex Hijacks TREM2's Synaptic Protective Binding Interface | C1QA/C1QB/C1QC, TREM2 | 0.500 | $0.52 | SDA-2026-04-16-gap-p |
| #314 | TREM2-Mediated Microglial Dysfunction Drives Tau-Induced Blood-Brain Barrier Breakdown | TREM2 | 0.499 | $0.00 | SDA-2026-04-03-26abc |
| #315 | TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1 Upregulation Through CSF1R-Mediated Survival and Metabolic Signaling | SPP1 | 0.496 | $0.50 | SDA-2026-04-06-gap-p |
| #316 | Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critical Neuroinflammatory Windows | NLRP3 | 0.496 | $0.00 | SDA-2026-04-15-gap-p |
| #317 | TREM2-Mediated Microglial Metabolic Reprogramming Accelerates Tau Pathological Spread | TREM2 | 0.494 | $0.00 | SDA-2026-04-03-26abc |
| #318 | YAP/TAZ Mechanosensing Cooperates with NF-κB to Amplify SPP1 Transcription in Perivascular Fibroblasts | SPP1 | 0.492 | $0.70 | SDA-2026-04-06-gap-p |
| #319 | GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling | GRIN2B | 0.491 | $0.00 | SDA-2026-04-03-26abc |
| #320 | P2RY12/P2RY13 Purinergic Receptor Metabolic Rewiring | P2RY12, P2RY13, CTNNB1 (β-catenin), GSK3β | 0.490 | $0.49 | SDA-2026-04-06-gap-p |
| #321 | Astrocyte Heterogeneity and Synapse-Specific Eat-Me Signal Expression | MFGE8, NPTX2 (Neuronal Pentraxin 1) | 0.490 | $0.49 | SDA-2026-04-07-gap-p |
| #322 | Testosterone-Derived DHT Amplifies Microglial Androgen Receptor Signaling Driving Male-Biased Neuroinflammation | AR | 0.490 | $0.49 | SDA-2026-04-06-gap-p |
| #323 | C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.489 | $0.49 | SDA-2026-04-16-gap-d |
| #324 | APOE4 Structural Remodeling via HSP70 Chaperone Enhancement Strategy | HSP70/APOE4 | 0.486 | $0.00 | SDA-2026-04-16-gap-d |
| #325 | TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation | TFEB | 0.485 | $0.00 | SDA-2026-04-03-gap-i |
| #326 | PINK1/PARK2-LC3 Mitophagy Enhancement | PINK1 | 0.485 | $0.48 | SDA-2026-04-03-gap-i |
| #327 | SIRT3 gates microglial surveillance versus primed metabolism through mitochondrial deacetylation | SIRT3 | 0.482 | $0.48 | SDA-2026-04-07-gap-d |
| #328 | Platelet-Derived PDGF-BB Primes VSMCs for P2RY12 Upregulation | PDGFB, PDGFRB | 0.480 | $0.48 | SDA-2026-04-07-gap-p |
| #329 | Ferroptosis as Context-Dependent and Motor Neuron-Subtype Selective | - | 0.475 | $0.53 | SDA-2026-04-18-gap-d |
| #330 | Cerebral VSMC foam cells induce pericyte detachment via PDGF-BB/VEGF imbalance, impairing neurovascular coupling | P2RY12 | 0.473 | $0.47 | SDA-2026-04-07-gap-p |
| #331 | Intranasal IGFBPL1 Delivery via Olfactory Pathway | IGFBPL1 | 0.470 | $0.47 | SDA-2026-04-06-gap-d |
| #332 | CD44-Mediated Src/PI3K/Akt Signaling Cascade | CD44, SRC, PI3K p85 (PIK3R1), MTOR | 0.470 | $0.47 | SDA-2026-04-06-gap-p |
| #333 | C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis | C1QA/C1QC | 0.470 | $0.47 | SDA-2026-04-07-gap-p |
| #334 | APOE and TREM2 interact to modulate age-dependent microglial dysfunction | TREM2 | 0.467 | $0.50 | aging-mouse-brain-20 |
| #335 | Cross-Tissue Communication Disruption | MULTIPLE | 0.466 | $0.51 | SDA-2026-04-16-gap-b |
| #336 | Source-Specific SPP1 Inhibition: Perivascular Cell Targeting | SPP1 (perivascular) | 0.466 | $0.47 | SDA-2026-04-07-gap-p |
| #337 | TYROBP Network Hyperactivation Marks Point of No Return | TYROBP/SYK axis, MAPK/ERK signaling | 0.463 | $0.46 | SDA-2026-04-06-gap-d |
| #338 | Microglial Priming Window for HDAC1-Dependent DAM Transition | HDAC1 | 0.463 | $0.46 | SDA-2026-04-07-gap-d |
| #339 | Necroptosis-cGAS Feedforward Loop Converts TDP-43 Pathology into Neuroinflammation | MLKL / RIPK1 | 0.460 | $0.46 | SDA-2026-04-07-gap-p |
| #340 | CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD | CSF neurofilament light (biomarker), lncRNA-0021, astrocyte-derived exosomes | 0.460 | $0.00 | SDA-2026-04-16-gap-p |
| #341 | Selective Microglial Senescence Targeting via TREM2 Modulation | TREM2 | 0.459 | $0.50 | SDA-2026-04-04-gap-s |
| #342 | Astrocytic SPP1 Modulation via STAT3-Dependent Transcriptional Control | SPP1 | 0.459 | $0.00 | SDA-2026-04-15-gap-p |
| #343 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.45 | SDA-2026-04-15-gap-p |
| #344 | Mitochondrial Damage-Triggered SPP1 Inflammasome Coupling | SPP1 | 0.453 | $0.00 | SDA-2026-04-15-gap-p |
| #345 | α4β1 Integrin (VLA-4) and JAK/STAT Pathway | ITGA4, ITGB1 (α4β1 heterodimer), JAK1/JAK2, STAT3 | 0.450 | $0.45 | SDA-2026-04-06-gap-p |
| #346 | Monocyte Trojan Horse Cell Therapy | IGFBPL1 | 0.450 | $0.45 | SDA-2026-04-06-gap-d |
| #347 | Astrocytic SPP1 Modulation for Neuroinflammatory Resolution | SPP1 | 0.447 | $0.00 | SDA-2026-04-15-gap-p |
| #348 | Microglial Membrane Camouflage Exploits CD47-SIRPα Checkpoint Disinhibition | CD47, SIRPA, PTPN6, PTPN11 | 0.444 | $0.46 | SDA-2026-04-16-gap-p |
| #349 | RAGE/STAT3/IL-6 Autocrine Loop Mediates Aβ-Induced SPP1 Upregulation in Perivascular Fibroblasts | SPP1 | 0.442 | $0.44 | SDA-2026-04-06-gap-p |
| #350 | DNA Hypomethylation at P2RY12 Promoter Correlates with Disease Progression | DNMT1, TET2 | 0.440 | $0.44 | SDA-2026-04-07-gap-p |
| #351 | KLF4-Mediated Transcriptional Repression of P2RY12 | KLF4 | 0.440 | $0.44 | SDA-2026-04-07-gap-p |
| #352 | Test: TREM2 enhances amyloid clearance | - | 0.437 | $0.44 | - |
| #353 | C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation via Microglial Receptor-Mediated Transcytosis | miR-33a/miR-33b | 0.427 | $0.00 | SDA-2026-04-16-gap-d |
| #354 | Lactate-HCAR1 signaling maintains a self-reinforcing glycolytic priming loop | HCAR1 | 0.427 | $0.43 | SDA-2026-04-07-gap-d |
| #355 | P2X7/P2Y12 Purinergic Signaling Connects Aβ Aggregation to SPP1 Transcription via Calcineurin/NFAT Pathway | SPP1 | 0.423 | $0.63 | SDA-2026-04-06-gap-p |
| #356 | C1q-Conjugated miR-33 ASO Brain Delivery for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.423 | $0.00 | SDA-2026-04-16-gap-d |
| #357 | LncRNA-HDAC1 Complex Formation Locks Microglia in Primed State | HDAC1/NEAT1 | 0.420 | $0.45 | SDA-2026-04-07-gap-d |
| #358 | IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | IGFBPL1 | 0.420 | $0.66 | SDA-2026-04-06-gap-d |
| #359 | P2RY12-mediated cerebral VSMC dysfunction establishes a vicious cycle with microglial P2RY12 activation | P2RY12 (dual: VSMC + microglia) | 0.418 | $0.42 | SDA-2026-04-07-gap-p |
| #360 | C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated Uptake and Redistribution | C1QBP | 0.415 | $0.47 | SDA-2026-04-17-gap-d |
| #361 | Test: TREM2 enhances amyloid clearance | - | 0.405 | $0.41 | - |
| #362 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #363 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #364 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #365 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #366 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.40 | - |
| #367 | CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics | CSF1R, nestin+ progenitor pool | 0.395 | $0.40 | SDA-2026-04-06-gap-d |
| #368 | BMAL1-CLOCK regulation of miR-143/145 locks microglia into glycolytic priming | ARNTL | 0.389 | $0.39 | SDA-2026-04-07-gap-d |
| #369 | Partial Agonist/SPP1 Splice Variant Strategy: Splice-Switching Therapeutics | SPP1 splicing factors | 0.375 | $0.41 | SDA-2026-04-07-gap-p |
| #370 | P2RY12 activation induces cellular senescence in cerebral VSMCs, driving neurodegeneration via SASP secretion | P2RY12 | 0.373 | $0.37 | SDA-2026-04-07-gap-p |
| #371 | Ferroptosis as Epiphenomenon of Terminal Collapse | - | 0.363 | $0.43 | SDA-2026-04-18-gap-d |
| #372 | Age-related neuroinflammation mimics early Alzheimer's disease pathology | GFAP | 0.362 | $0.50 | aging-mouse-brain-20 |
| #373 | Ferroptosis as Primary Driver of Motor Neuron Death | - | 0.339 | $0.40 | SDA-2026-04-18-gap-d |
| #374 | [Archived Hypothesis] | - | 0.300 | $0.30 | - |
| #375 | [Archived Hypothesis] | - | 0.300 | $0.30 | - |
| #376 | P2RY12 rs2046934 polymorphism modifies neurodegeneration risk by altering cerebral vascular autophagy capacity | P2RY12 (rs2046934) | 0.273 | $0.27 | SDA-2026-04-07-gap-p |
| #377 | TREM2 Agonism with CX3CR1 Antagonism for Microglial Homeostasis | - | 0.105 | $0.17 | SDA-NEUROINFLAM-BIOM |
| #378 | TYROBP Causal Network Inhibition for Microglial Repolarization | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |
| #379 | IL-33/ST2 Axis Augmentation for Synaptic Protection | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |
| #380 | P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |